Metformin for Weight Maintenance: Evidence, Off-Label Status, and Real Tradeoffs

Print or save as PDF

Is metformin approved for weight maintenance?

No. Metformin hydrochloride tablets are labeled as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients 10 years of age and older with type 2 diabetes mellitus; the extended-release tablets are labeled for adults with type 2 diabetes only [1][6]. Weight loss, weight maintenance, prediabetes prevention and PCOS are all outside the labeled indication [1]. Metformin is a generic, prescription-only oral biguanide [1].

What did the Diabetes Prevention Program actually measure?

The DPP randomized 3,234 non-diabetic adults with elevated fasting and post-load glucose concentrations — mean age 51, mean BMI 34.0, 68% women — to placebo, metformin 850 mg twice daily, or an intensive lifestyle program with goals of at least 7% weight loss and at least 150 minutes of physical activity per week. Mean follow-up was 2.8 years [2].

The trial's main outcome was diabetes incidence, but weight was measured throughout. During the double-blind phase, body weight fell 2.06% (SD 5.65) with metformin and 0.02% (SD 5.52) with placebo, P<0.001; waist circumference fell 2.13 cm versus 0.79 cm, P<0.001 [3]. The amount of weight lost was directly related to how closely people took the drug [3]. These are group averages, and the standard deviations show wide spread between individuals.

A 2015 meta-analysis of 257 randomized trials covering 54 drugs and 84,696 patients associated metformin with an average weight loss of 1.1 kg [7].

Does the difference hold up over years?

In the open-label extension after the double-blind period, weight loss stayed greater with metformin than with placebo — 2.0% versus 0.2% — across 7 to 8 years, and again was related to adherence [3].

The 15-year analysis speaks more directly to maintaining a loss, but it is a weaker study design. Of the 3,234 randomized participants, 1,066 lost at least 5% of baseline weight in year 1 and were followed for 15 years. After year 1, 28.5% of the metformin group, 62.6% of the lifestyle group and 13.4% of the placebo group had lost at least 5% of their weight. Between years 6 and 15, mean weight loss relative to baseline was 6.2% in the metformin group, 3.7% in the lifestyle group and 2.8% in the placebo group [4]. Continued metformin use and older age were independent predictors of maintained loss in the metformin group [4]. This is a post hoc analysis of non-randomized subsets, so the 6.2% figure does not show that metformin beats lifestyle change for keeping weight off in all users [4].

Does the diabetes benefit last?

In the DPP itself, diabetes incidence was 11.0 cases per 100 person-years with placebo, 7.8 with metformin and 4.8 with lifestyle. Metformin reduced incidence by 31% (95% CI 17 to 43%) and lifestyle by 58% (48 to 66%); lifestyle was significantly more effective than metformin. The number needed to treat over 3 years was 13.9 for metformin and 6.9 for lifestyle [2].

Across the DPP and its follow-up study, 2,776 participants were assessed over a mean of 15 years, with the metformin group receiving open-label metformin. Diabetes incidence was reduced by 27% with lifestyle (HR 0.73) and 18% with metformin (HR 0.82), compared with placebo, with the benefit shrinking over time. Cumulative incidence at 15 years was 55% with lifestyle, 56% with metformin and 62% with placebo. There was no overall difference in aggregate microvascular disease: 12.4% with placebo, 13.0% with metformin and 11.3% with lifestyle [5].

So the longest-running trial evidence shows a reduction in diabetes incidence that became smaller over time, alongside a weight difference of roughly 2% of body weight versus placebo.

What does metformin do that could affect weight?

The label describes metformin as decreasing hepatic glucose production, decreasing intestinal glucose absorption, and improving insulin sensitivity by increasing peripheral glucose uptake and utilization. Insulin secretion stays unchanged, while fasting insulin levels and the day-long insulin response may decrease [1].

Two research findings address mechanism. In hepatocytes, metformin activated AMP-activated protein kinase (AMPK), and AMPK activation was required for its inhibition of glucose production [8]. In 2020, researchers reported in Nature that metformin raises circulating GDF15, a hormone that reduces food intake and lowers body weight through a brainstem-restricted receptor; the human data came from two independent randomized controlled trials, and in mice the effects of metformin on body weight were lost when GDF15 or its receptor was absent [9].

Neither finding predicts how much weight any one person will lose. The trial averages are the better guide.

What does the label say to watch for?

Stomach and bowel effects. In a US trial of immediate-release metformin up to 2,550 mg a day in type 2 diabetes (141 patients on metformin, 145 on placebo), diarrhea occurred in 53% versus 12%, nausea or vomiting in 26% versus 8%, flatulence in 12% versus 6%, and diarrhea led to discontinuation in 6% [1]. In pooled placebo-controlled trials of extended-release metformin (781 on metformin, 195 on placebo), diarrhea occurred in 10% versus 3% and nausea or vomiting in 7% versus 2%, with diarrhea leading to discontinuation in 0.6% [6]. These results came from separate trials, so their adverse-event rates cannot be directly compared [1][6].

Vitamin B12. The label reports a fall to subnormal levels of previously normal serum vitamin B12 in approximately 7% of patients in 29-week trials, notes that the decrease appears to be rapidly reversible with discontinuation or B12 supplementation, and says to measure hematologic parameters annually and vitamin B12 at 2 to 3 year intervals and manage any abnormalities [1]. In DPPOS, low B12 (203 pg/mL or lower) occurred in 4.3% of metformin users versus 2.3% of placebo users at 5 years (P=0.02) and 7.4% versus 5.4% at 13 years (not significant). Combined low and borderline-low B12 (298 pg/mL or lower) was 19.1% versus 9.5% at 5 years and 20.3% versus 15.6% at 13 years. The odds of deficiency rose 13% for each year of metformin use (OR 1.13, 95% CI 1.06 to 1.20), and neuropathy was more common in metformin users with low B12 [10].

Lactic acidosis. This carries a boxed warning. Postmarketing cases have resulted in death, hypothermia, hypotension and resistant bradyarrhythmias, with a subtle onset of malaise, myalgias, respiratory distress, somnolence and abdominal pain. Named risk factors include renal impairment, carbonic anhydrase inhibitors such as topiramate, age 65 or older, contrast studies, surgery, hypoxic states such as acute heart failure, excessive alcohol intake, hepatic impairment and mitochondrial disease [1][6]. The label states that the postmarketing cases primarily occurred in patients with significant renal impairment [1]. A Cochrane review pooling 347 comparative trials and cohort studies in type 2 diabetes found no cases of fatal or nonfatal lactic acidosis in 70,490 patient-years of metformin use, with an upper limit for the true incidence of 4.3 cases per 100,000 patient-years [11].

Kidneys, contrast and alcohol. The label says to check eGFR before starting and at least yearly; metformin is contraindicated below 30 mL/min/1.73 m2, starting is not recommended at 30 to 45, and if eGFR later falls below 45 the benefit and risk of continuing should be reassessed, with discontinuation below 30 [1]. For patients with eGFR 30 to 60, a history of liver disease, alcoholism or heart failure, or when intra-arterial contrast is used, the immediate-release label calls for stopping metformin at the time of, or before, iodinated contrast imaging, re-checking eGFR 48 hours later and restarting only if renal function is stable [1]. Alcohol potentiates metformin's effect on lactate metabolism, and the label warns against excessive intake [1]. The label says metformin is not recommended in patients with hepatic impairment [1].

Low blood sugar. The label warns that hypoglycemia risk rises when metformin is combined with insulin or an insulin secretagogue such as a sulfonylurea, and that lower doses of those drugs may be needed [1].

Pregnancy. The label advises discussing the potential for an unintended pregnancy with premenopausal women, because metformin may result in ovulation in some anovulatory women [1].

What dose does the label specify?

For immediate-release tablets, the labeled starting dose is 500 mg twice a day or 850 mg once a day with meals, increased by 500 mg weekly or 850 mg every 2 weeks to a maximum of 2,550 mg a day in divided doses; doses above 2,000 mg may be better tolerated three times a day with meals [1]. The extended-release label instructs patients to swallow tablets whole without crushing, cutting or chewing, and gives a starting dose of 500 mg once daily with the evening meal, increasing by 500 mg weekly to a maximum of 2,000 mg once daily [6]. The DPP used 850 mg twice daily [2]. The label's titration is written for glycemic control in type 2 diabetes [1].

What about PCOS?

A 2017 Cochrane review of insulin-sensitising drugs in women with PCOS undergoing ovulation induction included 48 studies and 4,451 women, 42 of which investigated metformin (4,024 women). Evidence quality ranged from very low to moderate, and metformin may improve live birth rates compared with placebo (OR 1.59) [12]. The review's primary outcomes were live birth rate and gastrointestinal adverse effects, so it addresses fertility rather than weight maintenance [12].